Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most safety/monitoring and dosing-related details are not supported by the provided label excerpts; several specific numeric frequency claims and symptom lists are unsupported. No direct contraindication/boxed warning alignment can be assessed beyond general liver warnings.
Category Scores
Accurate Statements
In some individuals, Lipitor can cause liver damage.
SECTION 5.2 Liver Dysfunction (liver enzyme abnormalities/transaminase elevations; ALT/AST elevations) and SECTION 6 cross-reference to liver enzyme abnormalities.
Liver damage from Lipitor can lead to elevated liver enzymes.
SECTION 5.2 (persistent elevations in serum transaminases; recommendations related to ALT/AST).
Your doctor may recommend regular blood tests to check liver enzymes while taking Lipitor.
SECTION 5.2 (recommendation for liver function tests prior to and at 12 weeks following initiation and any elevation of dose, and periodically).
After changing a Lipitor dose, a doctor may recommend regular blood tests to check liver enzymes including alanine transaminase (ALT) and aspartate transaminase (AST).
SECTION 5.2 (liver function tests prior to and at 12 weeks following initiation and any elevation of dose; ALT/AST discussed in the excerpt).
If liver enzymes are elevated, a doctor may adjust the Lipitor dose or switch to a different medication.
SECTION 5.2 (if ALT/AST increase >3 times ULN persists: reduction of dose or withdrawal of LIPITOR is recommended).
If you experience liver-related symptoms while taking Lipitor, you should contact your doctor immediately.
SECTION 5.2 focuses on liver test monitoring and management based on ALT/AST elevations; no explicit “contact immediately” instruction is provided in the provided excerpts.
Unsupported Statements
Lipitor (atorvastatin) is a statin medication that reduces low-density lipoprotein (LDL) cholesterol in the blood.
The provided excerpts do not explicitly state LDL reduction as a label claim within the included text, though mechanism/clinical pharmacology sections are included generally; however, the statement is not directly supported by the supplied excerpts verbatim for this specific claim.
Lipitor helps prevent the buildup of plaque in the arteries that can lead to heart disease and stroke.
The provided label excerpts discuss risk reduction for MI/stroke and atherosclerosis promotion statements in clinical pharmacology, but do not explicitly claim “prevents buildup of plaque” wording.
Lipitor is processed by the liver and broken down into its active form.
The provided excerpts do not state atorvastatin is processed by the liver and broken down into an “active form.”
Liver damage from Lipitor can potentially even lead to liver failure.
The provided excerpts do not explicitly state liver failure as a consequence of liver damage due to Lipitor; postmarketing adverse reactions mention hepatic failure, but not as a consequence of liver damage.
According to the FDA, liver damage is a rare but serious side effect of Lipitor.
No “rare but serious” characterization for liver damage is provided in the excerpts.
In clinical trials, liver damage was reported in approximately 1 in 10,000 patients taking Lipitor.
No incidence/frequency number for liver damage is provided in the provided excerpts.
Symptoms of liver damage from Lipitor may include fatigue.
The provided excerpts do not provide a symptom list for liver dysfunction (fatigue not listed as a symptom in the excerpts).
Symptoms of liver damage from Lipitor may include loss of appetite.
Not supported by the provided excerpts.
Symptoms of liver damage from Lipitor may include nausea and vomiting.
Not supported by the provided excerpts.
Symptoms of liver damage from Lipitor may include abdominal pain.
Not supported by the provided excerpts.
Symptoms of liver damage from Lipitor may include yellowing of the skin and eyes (jaundice).
Not supported by the provided excerpts.
Symptoms of liver damage from Lipitor may include dark urine.
Not supported by the provided excerpts.
Symptoms of liver damage from Lipitor may include pale stools.
Not supported by the provided excerpts.
If you experience liver-related symptoms while taking Lipitor, your doctor may adjust your Lipitor dose or switch you to a different medication.
The provided excerpts provide dose reduction/withdrawal recommendations based on persistent ALT/AST elevations, but do not link management specifically to experiencing “liver-related symptoms.”
Contradictions
Important Omissions
The response does not include the label-supported thresholds and guidance for management (e.g., persistent ALT/AST elevations >3 times ULN on 2 or more occasions; reduction of dose or withdrawal recommended).
Importance:
Moderate
The response does not mention that LIPITOR is contraindicated in active liver disease (active liver disease/unexplained persistent elevations in hepatic transaminases) as provided in the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported symptom lists and numeric frequency claims could mislead risk perception; monitoring/dose-adjustment statements are partially aligned with label testing guidance, but the response lacks key threshold-based management details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple liver-safety assertions (frequency estimate, liver failure linkage, and detailed symptom lists) are not supported by the provided label excerpts.
Suggested Improvement
Restrict liver-related claims to the label-supported monitoring and management language (ALT/AST elevations, testing timing, and “if ALT/AST >3× ULN persist, reduction of dose or withdrawal is recommended”), and remove unsupported incidence/symptom frequency/details unless directly quoted from the prescribing information excerpts provided.